European Journal of Hybrid Imaging (Nov 2017)

Targeted 11C–choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy

  • Massimo Lazzeri,
  • Egesta Lopci,
  • Giovanni Lughezzani,
  • Piergiuseppe Colombo,
  • Paolo Casale,
  • Rodolfo Hurle,
  • Alberto Saita,
  • Lorenzo Leonardi,
  • Giuliana Lista,
  • Roberto Peschechera,
  • Luisa Pasini,
  • Marcello Rodari,
  • Silvia Zandegiacomo,
  • Alessio Benetti,
  • Pasquale Cardone,
  • Federica Mrakic,
  • Luca Balzarini,
  • Arturo Chiti,
  • Giorgio Guazzoni,
  • Nicolò Maria Buffi

DOI
https://doi.org/10.1186/s41824-017-0011-1
Journal volume & issue
Vol. 1, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background We evaluated the feasibility and accuracy of 11C–choline PET-CT/TRUS fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI or contraindication to MRI, after previous negative biopsy. Clinical data were part of a prospective on-going observational clinical study: “Diagnostic accuracy of target mpMRI/US fusion biopsy in patients with suspected prostate cancer after initial negative biopsy”. Patients with a negative biopsy and negative mpMRI (PI-RADS v.2 6. Over 58 cores, 25 (43.1%) were positive. No statistically significant difference in terms of mean and median values for SUVmax and SUVratio between benign and malignant lesions was found. PCa lesions with GS 3 + 3 (n = 3) showed a median SUVmax and SUVratio of 4.01 and 1.46, compared to 5.45 and 1.57, respectively for lesions with GS >6 (n = 4). Conclusion Software PET-CT/TRUS fusion-guided target biopsy could be a diagnostic alternative in patients with a suspected primary PCa and negative mpMRI, but its specificity appeared low.